4.2 Review

The Real Role of β-Blockers in Daily Cardiovascular Therapy

Journal

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
Volume 17, Issue 5, Pages 361-373

Publisher

ADIS INT LTD
DOI: 10.1007/s40256-017-0221-8

Keywords

-

Ask authors/readers for more resources

The role of beta-adrenoceptor antagonists (beta-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, beta-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the respective medical societies for heart failure, coronary artery disease, and atrial fibrillation as well as in hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. When indicated, cardioselective beta-blockers should be prescribed in patients with diabetes mellitus or chronic obstructive pulmonary disease. We review the available evidence for the use of beta-blockers in clinical conditions in which recommendations can be made for everyday practice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available